The Joint Corp. (JYNT) Given Consensus Rating of “Buy” by Brokerages
The Joint Corp. (NASDAQ:JYNT) has earned an average rating of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.15.
A number of brokerages have weighed in on JYNT. Maxim Group restated a “buy” rating and issued a $7.00 target price on shares of The Joint Corp. in a research report on Friday, August 11th. Zacks Investment Research upgraded shares of The Joint Corp. from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a report on Wednesday, September 27th. Finally, Roth Capital started coverage on shares of The Joint Corp. in a report on Thursday, July 27th. They set a “buy” rating and a $5.70 price target on the stock.
The Joint Corp. (NASDAQ:JYNT) opened at $4.70 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.22 and a current ratio of 1.22.
The Joint Corp. (NASDAQ:JYNT) last issued its earnings results on Thursday, August 10th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. The Joint Corp. had a negative net margin of 48.08% and a negative return on equity of 103.25%. The firm had revenue of $6.02 million for the quarter, compared to analyst estimates of $5.76 million. research analysts expect that The Joint Corp. will post -0.3 EPS for the current fiscal year.
WARNING: “The Joint Corp. (JYNT) Given Consensus Rating of “Buy” by Brokerages” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/04/the-joint-corp-jynt-given-consensus-rating-of-buy-by-brokerages.html.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sanders Morris Harris LLC raised its stake in The Joint Corp. by 0.5% during the second quarter. Sanders Morris Harris LLC now owns 2,619,807 shares of the company’s stock worth $9,955,000 after buying an additional 12,000 shares during the last quarter. Captrust Financial Advisors bought a new position in The Joint Corp. during the second quarter worth $791,000. Boston Partners raised its stake in The Joint Corp. by 25.4% during the third quarter. Boston Partners now owns 189,200 shares of the company’s stock worth $901,000 after buying an additional 38,300 shares during the last quarter. Russell Investments Group Ltd. raised its stake in The Joint Corp. by 24.9% during the second quarter. Russell Investments Group Ltd. now owns 87,900 shares of the company’s stock worth $334,000 after buying an additional 17,500 shares during the last quarter. Finally, White Pine Capital LLC raised its stake in The Joint Corp. by 44.2% during the second quarter. White Pine Capital LLC now owns 55,500 shares of the company’s stock worth $211,000 after buying an additional 17,000 shares during the last quarter. 46.90% of the stock is owned by institutional investors and hedge funds.
The Joint Corp. Company Profile
The Joint Corp. develops, owns, operates, supports and manages chiropractic clinics through direct ownership, management arrangements, franchising and the sale of regional developer rights throughout the United States. The Company is franchisor and operator of chiropractic clinics. The Company offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention.
Receive News & Ratings for The Joint Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Joint Corp. and related companies with MarketBeat.com's FREE daily email newsletter.